Abstract:Menopause predisposes women to osteoporosis due to declining estrogen levels. This results in a decrease in bone mineral density (BMD) and an increase in fractures. Osteoporotic fractures lead to substantial morbidity and mortality, and are considered one of the largest public health priorities by the World Health Organization (WHO). It is therefore essential for menopausal women to receive appropriate guidance for the prevention and management of osteoporosis. The Women’s Health Initiative (WHI) randomized controlled trial first proved hormonal therapy (HT) reduces the incidence of all osteoporosis-related fractures in postmenopausal women. However, the study concluded that the adverse effects outweighed the potential benefits on bone, leading to a significant decrease in HT use for menopausal symptoms. Additionally, HT was not used as first-line therapy for osteoporosis and fractures. Subsequent studies have challenged these initial conclusions and have shown significant efficacy of HT in various doses, durations, regimens, and routes of administration. These studies support that HT improves BMD and reduces fracture risk in women with and without osteoporosis. Furthermore, the studies suggest that low-dose and transdermal HT are less likely associated with the adverse effects of breast cancer, endometrial hyperplasia, coronary artery disease (CAD), and venous thromboembolism (VTE) previously observed in standard-dose oral HT regimens. Given the need for estrogen in menopausal women and evidence supporting the cost effectiveness, safety, and efficacy of HT, we propose that HT should be considered for the primary prevention and treatment of osteoporosis in appropriate candidates. HT should be individualized and the once “lowest dose for shortest period of time” concept should no longer be used. This review will focus on the prior and current studies for various HT formulations used for the prevention and treatment of osteoporosis, exploring the safety profile of low-dose and transdermal HT that have been shown to be safer than oral standard-dose HT.

Postmenopausal Osteoporosis Treated by Hormone Replacement Therapy (HRT) with Small Dose of Estrogen

Preventive Effects of Small Dose Estrogen and Progesterone on Prevention and Treatment of Perimenopausal Osteoporosis

A 1-year randomized, placebo-controlled, double blind, parallel-group trial of a combined oral estrogen/progestogen preparation on cardiovascular risk factors, and bone mineral density

Contrast study of validity and safety of low dosage of complex prescription nilestriol tablets and tibolone in treatment of the elderly women with osteoporosis

The effect of low dose nylestriol-levonorgestrel replacement therapy on bone mineral density in women with postmenopausal osteoporosis

Prevention of Postmenopausal Osteoporosis in Chinese Women: a 5-Year, Double-Blind, Randomized, Parallel Placebo-Controlled Study

Observation and surveillance for low-dose HRT

Meta-analysis exploring the effectiveness and safety of different doses of estrogen in the treatment of osteoporosis in perimenopausal women in China

Estrogen therapy for osteoporosis in the modern era

Efficacy and safety evaluation of standardized management of hormone therapy in menopausal women

Effect of combined oral estrogen/progestogen preparation (Kliogest) on bone mineral density, plasma lipids and postmenopausal symptoms in HRT-naïve Thai women

Clinical Efficacy Observation of Recombinant Human Parathyroid Hormone 1-34(Rhpth1-34)combined with Caltrate D in Treatment of Post Menopausal Women with Osteoporosis

Effects of Tibolone Replacement Therapy on Coagulation and Fibrinolysis of Postmenopausal Women with Hypertension

[Preventing of postmenopausal osteoporosis by hormone replacement therapy? Is the risk acceptable?]

Hormone replacement therapy(HRT) in women with a prior diagnosis of ovarian and cervical cancer

The Effect of Serum Contained Nilestriol on the Expression of Transforming Growth Factor -Β1 and Its Signal Transduction Molecule Smad4 in the Rat Osteoblasts

Experimental study of compound nylestriol tablet on rats with osteoporosis induced by ovariectomy

Clinical observation of Zoledronic acid combined with estradiol valerate and cyproterone acetate in the treatment of secondrary osteoporosis caused by premature ovarian failure

Effectof Hormone Replacement Therapy ( Hrt) on Depression in Perimenopausal Women.

Hormones, herbal preparations and nutriceuticals for a better life after the menopause: part I

The First Multicenter and Randomized Clinical Trial of Herbal Fufang for Treatment of Postmenopausal Osteoporosis